Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Analyst Firms Making Recommendations1
- Cantor Fitzgerald
- JP Morgan
- Canaccord Genuity
- Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ACADIA Pharmaceuticals
What is the target price for ACADIA Pharmaceuticals (ACAD)?
The latest price target for ACADIA Pharmaceuticals (NASDAQ: ACAD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $42.00 expecting ACAD to rise to within 12 months (a possible 101.54% upside). 49 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ACADIA Pharmaceuticals (ACAD)?
The latest analyst rating for ACADIA Pharmaceuticals (NASDAQ: ACAD) was provided by Cantor Fitzgerald, and ACADIA Pharmaceuticals reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for ACADIA Pharmaceuticals (ACAD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ACADIA Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ACADIA Pharmaceuticals was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
Is the Analyst Rating ACADIA Pharmaceuticals (ACAD) correct?
While ratings are subjective and will change, the latest ACADIA Pharmaceuticals (ACAD) rating was a reiterated with a price target of $0.00 to $42.00. The current price ACADIA Pharmaceuticals (ACAD) is trading at is $20.84, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.